Elsevier

Biochemical Pharmacology

Volume 40, Issue 12, 15 December 1990, Pages 2651-2660
Biochemical Pharmacology

Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells

https://doi.org/10.1016/0006-2952(90)90583-7Get rights and content

Abstract

Previous studies have suggested that metabolic inhibition by methotrexate (MTX) is multifactorial and that cytotoxicity can be reversed by the reduced folate leucovorin. In this report we investigated the mechanism of leucovorin rescue in the MCF-7 human breast cancer cell line. Cells were exposed to various concentrations of MTX (0.5, 1.0, 3.0, and 10.0 μM) for 24 hr followed by rescue with labelled leucovorin (0.5 to 50 μM). The changes in the intracellular folate pools 24 hr following the addition of leucovorin were quantitated by high-pressure liquid Chromatographie methods. The changes in the folate pools during rescue were compared with the ability of various concentrations of leucovorin to affect cellular rescue from MTX using a cloning assay. Our studies show that the total labelled intracellular folate pools increased in a log-linear fashion with respect to leucovorin exposure concentrations up to 100 μM. The degree of accumulation at a given leucovorin concentration was not significantly different in the absence or presence of MTX over the concentration range of 0.5 to 10 μM. Individual folate pool levels (tetrahydrofolate, 10-formyl tetrahydrofolate, 5-formyl tetrahydrofolate, 5-methyl tetrahydrofolate, and 5,10-methylene tetrahydrofolate) reached those present in cells not exposed to MTX at concentrations of leucovorin that were not adequate to rescue the MTX-treated cells. With exposure to concentrations of leucovorin capable of rescue, the individual folate pool levels were up to twelve times greater than those found in untreated cells, consistent with competition for catalytic activity at folate-dependent enzymes in addition to dihydrofolate reductase. The dihydrofolate pool also increased with increasing leucovorin concentration; but, unlike the reduced folates, this oxidized folate reached a maximal level that was dependent on the MTX concentration to which the cells had been exposed. This suggests that competition between MTX and leucovorin occurs at the level of dihydrofolate reductase via a competitive interaction with dihydrofolate in this intact cell system. The ability of leucovorin and its metabolites to compete with direct inhibitors of dihydrofolate reductase and other metabolically important folate-dependent enzymes appears to be associated with leucovorin rescue.

References (44)

  • JC White

    Reversal of methotrexate binding to dihydrofolate reductase by dihydrofolate: Studies with pure enzyme and computer modeling network thermodynamics

    J Biol Chem

    (1979)
  • RC Jackson et al.

    Reactivation of dihydrofolate reduction inhibited by methotrexate or aminopterin

    Arch Biochem Biophys

    (1977)
  • MC Waltham et al.

    Direct experimental evidence for competitive inhibition of dihydrofolate reductase by methotrexate

    Biochem Pharmacol

    (1988)
  • KE McMartin et al.

    High pressure liquid chromatography: Separation and determination of rat liver folates

    Arch Biochem Biophys

    (1981)
  • E Chu et al.

    Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells

    J Biol Chem

    (1990)
  • M Bradford

    A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

    Anal Biochem

    (1976)
  • RB Rees et al.

    Methotrexate for psoriasis

    Arch Dermatol

    (1967)
  • RC Jackson et al.

    Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrofolate reductase

    Cancer Res

    (1980)
  • P Kumar et al.

    Interaction of polyglutamyl derivatives of MTX, 10-deazaaminopterin, and di-hydrofolate with dihydrofolate reductase

    Cancer Res

    (1986)
  • J Baram et al.

    Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow

    J Clin Invest

    (1987)
  • LH Matherly et al.

    The effects of 4-amino-antifolates on 5- formyltetrahydrofolate metabolism in L1210 cells

    J Biol Chem

    (1987)
  • Cited by (22)

    • Supramolecular encapsulation of nanocrystalline Schiff bases into β-cyclodextrin for multifold enrichment of bio-potency

      2022, Carbohydrate Polymers
      Citation Excerpt :

      In brief, MCF-7 cells were seeded in 24-well culture plates (105 cells/well) in a complete medium. After 24 h, MCF-7 cells were treated with four best doses (10 μM, 20 μM, 40 μM, 80 μM), DMSO as vehicle control, and methotrexate (10 μM) as the positive control (Boarman, Baram, & Allegra, 1990); for time-dependent experiments, cells were treated with specific concentrations of crude extract in fresh medium for 24 and 48 h. After treatments, cells were harvested by chilled PBS, fixed for 5 min at −20 °C in methanol, then washed and re-suspended in 1 mL PBS buffer.

    • Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia – How much is just right?

      2021, Gynecologic Oncology
      Citation Excerpt :

      FA may either aid or hinder chemotherapy. Since FA competes with MTX in its action on dihydrofolate reductase, its use may limit toxicity and allow treatment to be continued, alternatively, excessive FA may prevent the inhibition of dihydrofolate reductase and might decrease the efficacy of MTX and decrease the remission rate or increase the occurrence of relapse, as described in cases of lymphoblastic leukemia and non-Hodgkin lymphoma [13–15]. Additionally, FA may increase the overall cost of therapy.

    • Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder

      2020, Seminars in Pediatric Neurology
      Citation Excerpt :

      The improvement in an important symptom associated with ASD, irritability, suggests that d,l-leucovorin may be an alternative to antipsychotic drugs, which have significant short- and long-term AEs in children. Additionally, d,l-leucovorin can normalize folate-dependent one-carbon metabolism by readily entering the folate cycle without being reduced by dihydrofolate reductase (DHFR in Fig. 1).83 Early studies on CFD and ASD demonstrated a strong positive effect of d,l-leucovorin in young children with ASD on both neurologic and cognitive development.22

    • Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX)

      2013, Medical Hypotheses
      Citation Excerpt :

      When the dose of MTX was doubled, the dose of FA needed to maintain the increased life span and avoid toxic deaths rose by 3.3-fold in the leukemia group (to 400 mg/kg) and 4-fold in the sarcoma group (to 288 mg/kg). Pinedo [14] and Boarman [15] Koizumi [16] reported similar findings. Bertino [11], noted that, “If LV administration is delayed for more than 42 or 48 h following HD MTX, severe and irreversible toxicity may occur”.

    • Leucovorin-induced resistance against FDH growth suppressor effects occurs through DHFR up-regulation

      2006, Biochemical Pharmacology
      Citation Excerpt :

      In the cell, excess leucovorin is rapidly converted to 5,10-methenyl-THF and then to 5,10-methylene-THF [32]. Alterations in intracellular reduced folate pools in response to leucovorin supplementation are one of the mechanisms of rescue from MTX toxicity [10,33,34]. On the other side, elevation of intracellular 5,10-methylene-THF is the basis for the application of leucovorin in combination with 5-fluorouracil, an inhibitor of thymidylate synthase, in cancer chemotherapy.

    View all citing articles on Scopus
    View full text